Vyndaqel
![](https://familymednews.com/wp-content/uploads/sites/15/2018/04/hlEkZEkoAFOdOleNHWuK-900x280.jpg)
January 14, 2019 – Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company’s New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete […]
Continue reading »